Inhibikase Therapeutics, Inc.

📍 ATLANTA, United States👥 8 employees💰 Last funded Mar 2019
Pharmaceutical Manufacturing🌐 inhibikase.com
Website LinkedIn
Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional reversal inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Inhibikase Therapeutics, Inc.?
Inhibikase Therapeutics, Inc. has 2 investors on record on gritt.io.
When did Inhibikase Therapeutics, Inc. last raise funding?
The most recent investment in Inhibikase Therapeutics, Inc. recorded on gritt.io was in March 2019.
What industry is Inhibikase Therapeutics, Inc. in?
Inhibikase Therapeutics, Inc. operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Inhibikase Therapeutics, Inc. based?
Inhibikase Therapeutics, Inc. is headquartered in ATLANTA, United States.